Under the terms of the relationship, Corgenix’s AspirinWorks product will be used to assess aspirin effect as part of SpectraCell’s cardiovascular risk assessment services.
The collaboration will allow SpectraCell to take advantage of Corgenix’s diagnostic assay that determines the effect of aspirin on platelets in apparently healthy individuals by measuring the level of thromboxane production (aspirin’s target), said Corgenix.
Fred Crawford, vice president of operations and technical director at SpectraCell, said: “This arrangement further expands our functional testing capabilities to include aspirin effect. Partnering with Corgenix helps insure that SpectraCell continues to deliver the most advanced technology and highest quality service to our physician clients nationwide.”